Skip to content
Our Latest News, Case Studies, Webinars & More
The Role of Enhanced Due Diligence in Pharma M&A
Mergers and acquisitions in the life sciences sector can rapidly expand a company’s scientific capabilities, geographic reach, and market access — but[...]
Navigating the New BIS Landscape: Why a Risk-Based Approach Matters More Than Ever
The U.S. Department of Commerce’s Bureau of Industry and Security (BIS) has long used the Entity List to restrict exports to organizations and individuals engaged in activities contrary to U.S. [...]
What the new BIS 50% Rule Means for Third-Party Screening & Ownership Due Diligence
On September 29, 2025, the Bureau of Industry and Security of the US Department of Commerce (“BIS”) issued a new interim final rule [...]
The Importance of TPRM in Facilitating Ethical Transactions with HCPs
In the Life Sciences industry, maintaining ethical and transparent relationships with healthcare professionals (HCPs) is fundamental to trust, patient safety, and business integrity. [...]
Agility, Innovation & Strong (Ethical) Foundations
Earlier this month, Ethixbase360 was delighted to sponsor the third annual Risk & Compliance Pharma & Life Sciences Conference, held in London. [...]
The Case for Integrity: How SMEs Can Leverage Ethical Business Practices for Growth
In today’s business environment, where regulators and customers are increasingly vigilant about transparency and integrity, ethical business practices have shifted from a compliance
Hospitality vs. Bribery: Navigating Compliance Risks at Corporate Events
At Ethixbase360, we’re proud to support the next generation of compliance and risk management professionals. As part of our summer […]
Factoring AI into Supply Chain Governance
Today, it’s nearly impossible to avoid the furor over artificial intelligence. What was once confined to the pages of speculative […]
